A major collaborative research project “Artificial Intelligence and Genomics to Predict Cancer Treatment” has been awarded a $2.6 million CRC-P Grant (Cooperative Research Centre Projects) by Australian Government. BGI is the Next-Gen Sequencing partner of the Project, in collaboration with other world leading partners including Max Kelsen the leading partner specialising in artificial intelligence technology, QIMR Berghofer Medical Research Institute as the research partner, Queensland Health Metro North Hospital and Health Service as the clinical partner, and genomiQa as the bioinformatic analysis partner. The Project has to date attracted $6.4 million of cash and in-kind contributions from industry partners.
BGI and Maxwell Plus have executed a collaborative cancer research project “A model to predict risk of developing advanced or metastatic prostate cancer using genetic makeup and family history of cancers” in September 2018. Prostate cancer is the second most common type of cancer among males in Western countries, with an estimated 165,000 new cases and 29,500 cancer deaths in 2018 alone. The objective of the project is to understand the genetic makeup of prostate cancer patients and understand how significant the association is between prevalence of prostate, breast, ovarian and colorectal cancers in the families of patients. The risk of the genetic makeup and family history will be combined into a risk model for predicting advanced or metastatic prostate cancer. This project will provide significant research merit for cancer analysis, cancer discovery, and precision medicine. All samples will be sequenced on the cutting-edge BGI genetic sequencer, MGISEQ-2000, in the BGI Australia laboratory.
BGI is a pioneer in developing genomics-based solutions across the reproductive health and women's health continuum. BGI's market-leading non-invasive prenatal test (NIPT), the NIFTY® test (Non-Invasive Fetal TrisomY test), was one of the first NIPTs on the market and has been trusted by over 4 million patients worldwide to date. NIFTY® is a safe, simple, non-invasive prenatal test which offers screening for certain genetic conditions from as early as week 10 of pregnancy. Using the latest genetic sequencing technology, NIFTY® has over >99% accuracy for the three most common trisomy conditions present at birth, which are Down Syndrome, Edwards Syndrome and Patau Syndrome. To find out more about NIFTY®, please visit here.
BGI also offers a wide range of other genetic tests for Australia including VISTA™ Carrier Screening, VISTA™ PGS (Pre-implantation Genetic Screening), and VISTA™ Chromosome Sequencing. We continually seek to support and be involved in maternal and child health research in Australia.
BGI's genetic tests and diagnostic solutions are provided by BGI Genomics, an independent subsidiary under BGI Group.
BGI's genetic tests, reproductive health, NIPT, non-invasive prenatal genetic test, VISA newborn genetic test
BGI is also engaging in extensive plant and animal research covering a variety of fields including agriculture, species conservation and improvement, and ecological management and restoration. BGI has led and participated in numerous international collaborative research projects including 1000 Plant Genomes Project (1KP), the Genome 10K (G10K) Consortium, International Giant Panda Genome Project, Cucumber Genome project, Orchid Genome Project, Silkworm Genome Resequencing, Soybean genome Resequencing 1,000 Plants (1KP) Project, "Three Poles" Animal Genomes Project, and more.
In Australia, BGI is proud to be involved in a five-year $13.3 million tree DNA horticulture project, which will make it easier to develop fruit trees and nut trees that are resistant to drought and disease. Delivered through Hort Innovation under the Hort Frontiers strategic partnership initiative, the project will develop a breeders genomic tool kit for tree breeders and researchers to better understand how genes control traits that are valuable to Australian growers - such as tree size, yield, disease resistance, and tree maturity. The project aims to build a complete DNA map that will visualise the genetic make-up and variability of the nation’s five (5) leading tree crops including avocados, mango, macadamia, almond and citrus fruit varieties, which represents 80% of the total volume of horticultural tree crop production in Australia. The research will be conducted by the Queensland Alliance for Agriculture and Food Innovation (QAAFI) and the Queensland University of Technology (QUT). BGI is the industry partner of the Project.
BGI Genomics, an independent subsidiary of BGI Group, also offers a wide range of agricultural genomics (agri-genomics) solutions, which are helping to drive both increased food supply and sustainable production. Our agri-genomics technologies are helping plant and animal breeders and researchers identify desirable traits, leading to healthier and more productive crops and livestock.
plant and animal research covering agriculture, species conservation, and ecological restoration
Forensic Genomics International (FGI), a forensics subsidiary of BGI Group, has serviced over 200,000 satisfied customers with an accuracy of 99.99999%. FGI tests 23 genetic markers to ensure the most accurate results possible in just 5 working days. With the highest standards and strictest quality control in the laboratory testing, FGI services are also available for Australia and New Zealand including Non-invasive Prenatal Paternity Test, Animal Profiling, DNA Test for IVF Babies, and more. For more information please download the product brochures below. For forensic service inquires or interest for partnership opportunities please contact our BGI Australia office at firstname.lastname@example.org.
High-accuracy Forensic DNA Testing, BGI, NIPPT, non-invasive prenatal paternity test